Literature DB >> 18216457

Pain relief after cervical ganglionectomy (C2 and C3) for the treatment of medically intractable occipital neuralgia.

Feridun Acar1, Jonathan Miller, Kiarash J Golshani, Zvi H Israel, Shirley McCartney, Kim J Burchiel.   

Abstract

Occipital neuralgia (ON) presents a diagnostic challenge because of the wide variety of symptoms, surgical findings, and postsurgical outcomes. Surgical removal of the second (C2) or third (C3) cervical sensory dorsal root ganglion is an option to treat ON. The goal of this study was to evaluate the short-term and the long-term efficacy of these procedures for management of cervical and occipital neuropathic pain. Twenty patients (mean age 48.7 years) were identified who had undergone C2 and/or C3 ganglionectomies for intractable occipital pain and a retrospective chart review undertaken. Patients were interviewed regarding pain relief, pain relief duration, functional status, medication usage and procedure satisfaction, preoperatively, immediately postoperative, and at follow-up (mean 42.5 months). C2, C3 and consecutive ganglionectomies at both levels were performed on 4, 5, and 11 patients, respectively. All patients reported preoperative pain relief following cervical nerve blocks. Average visual analog scale scores were 9.4 preoperatively and 2.6 immediately after procedure. Ninety-five percent of patients reported short-term pain relief (<3 months). In 13 patients (65%), pain returned after an average of 12 months (C2 ganglionectomy) and 8.4 months (C3 ganglionectomy). Long-term results were excellent, moderate and poor in 20, 40 and 40% of patients, respectively. Cervical ganglionectomy offers relief to a majority of patients, immediately after procedure, but the effect is short lived. Nerve blocks are helpful in predicting short-term success, but a positive block result does not necessarily predict long-term benefit and therefore cannot justify surgery by itself. However, since 60% of patients report excellent-moderate results, cervical ganglionectomy continues to have a role in the treatment of intractable ON. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18216457     DOI: 10.1159/000113872

Source DB:  PubMed          Journal:  Stereotact Funct Neurosurg        ISSN: 1011-6125            Impact factor:   1.875


  6 in total

1.  Routine sectioning of the C2 nerve root and ganglion for C1 lateral mass screw placement in children: surgical and functional outcomes.

Authors:  Akash J Patel; Loyola V Gressot; Jerome Boatey; Steven W Hwang; Alison Brayton; Andrew Jea
Journal:  Childs Nerv Syst       Date:  2012-09-27       Impact factor: 1.475

2.  C1 lateral mass screw placement with intentional sacrifice of the C2 ganglion: functional outcomes and morbidity in elderly patients.

Authors:  Jason Squires; Robert W Molinari
Journal:  Eur Spine J       Date:  2010-05-22       Impact factor: 3.134

3.  Pulsed radiofrequency of the second cervical ganglion (C2) for the treatment of cervicogenic headache.

Authors:  Juan Zhang; Dong-sheng Shi; Rui Wang
Journal:  J Headache Pain       Date:  2011-05-25       Impact factor: 7.277

4.  Functional and Molecular Analysis of Proprioceptive Sensory Neuron Excitability in Mice.

Authors:  Jessica F Madden; Olivia C Davis; Kieran A Boyle; Jacqueline A Iredale; Tyler J Browne; Robert J Callister; Douglas W Smith; Phillip Jobling; David I Hughes; Brett A Graham
Journal:  Front Mol Neurosci       Date:  2020-05-05       Impact factor: 5.639

5.  Pain modulation effect on motor cortex after optogenetic stimulation in shPKCγ knockdown dorsal root ganglion-compressed Sprague-Dawley rat model.

Authors:  Jaisan Islam; Elina Kc; Byeong Ho Oh; Hyeong Cheol Moon; Young Seok Park
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

Review 6.  A Review of the Recent Findings in Minimally Invasive Treatment Options for the Management of Occipital Neuralgia.

Authors:  Ivan Urits; Ruben H Schwartz; Parth Patel; Justin Zeien; Denton Connor; Jamal Hasoon; Amnon A Berger; Hisham Kassem; Laxmaiah Manchikanti; Alan D Kaye; Omar Viswanath
Journal:  Neurol Ther       Date:  2020-06-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.